Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-09-28
Intellia Therapeutics, Inc.
Intellia is a clinical-stage biotechnology company developing one-time CRISPR-based gene editing therapies, led by lonvo-z for hereditary angioedema and nex-z for ATTR amyloidosis.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

First Approval Could Change the Business Model
This is a narrow but attractive rare-disease setup: one regulatory win can turn a platform story into owned commercial revenue. The likely upside is meaningful, but it still depends on proving that approval converts into payer-backed adoption and that ATTR regains credibility.

Analysis

Thesis
If lonvo-z converts its March 10, 2027 FDA date into a clean launch, Intellia can shift from collaboration-funded R&D into an owned-product rare-disease company; partial de-risking of nex-z, ex-U.S. licensing and selective data monetization make the 2031 revenue curve meaningfully non-linear without requiring a full platform-mania rerating.
Last Economy Alignment
AI helps Intellia design, interpret and execute faster, but value still turns on regulatory trust, clinical proof and specialized launch workflows rather than pure software scale.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.2x (from 5 most recent analyses)
Reasoning
The upside is mainly a business-model change, not just a better science narrative. A successful lonvo-z launch would create owned product revenue, improve financing leverage and raise the credibility of every follow-on program. I stop short of a full platform premium because irreversible editing should remain concentrated in rare disease and ATTR is still only partly de-risked.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The setup is attractive because one approval can change the business model quickly, but the path is narrow. The main risks are lonvo-z review and launch conversion, nex-z safety and Phase 3 execution, and the cash demands of becoming a first-launch gene-editing company before durable product revenue is proven.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.37
They do not sell AI itself; they sell regulated gene-editing medicines. AI helps them design and learn faster, but the real control point is approval plus trusted treatment workflows, and safety setbacks can still break the flywheel.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$24.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case